Table of Contents Author Guidelines Submit a Manuscript
Journal of Diabetes Research
Volume 2013 (2013), Article ID 563919, 6 pages
http://dx.doi.org/10.1155/2013/563919
Research Article

Relevance of Plasma Obestatin and Early Arteriosclerosis in Patients with Type 2 Diabetes Mellitus

1Department of Geriatric Medicine, Anhui Provincial Hospital Affiliated to Anhui Medical University, Hefei, Anhui 230001, China
2Department of Endocrine Laboratory, Anhui Provincial Hospital Affiliated to Anhui Medical University, Hefei, Anhui 230001, China
3Department of Ultrasonic Medicine, Anhui Provincial Hospital Affiliated to Anhui Medical University, Hefei, Anhui 230001, China
4Department of Clinical Laboratory, Anhui Provincial Hospital Affiliated to Anhui Medical University, Hefei, Anhui 230001, China
5Department of Endocrinology, Anhui Provincial Hospital Affiliated to Anhui Medical University, Hefei, Anhui 230001, China

Received 22 May 2013; Revised 4 September 2013; Accepted 10 September 2013

Academic Editor: Giuseppe Paolisso

Copyright © 2013 Peng-ying Gu et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. J. A. Beckman, M. A. Creager, and P. Libby, “Diabetes and atherosclerosis epidemiology, pathophysiology, and management,” Journal of the American Medical Association, vol. 287, no. 19, pp. 2570–2581, 2002. View at Google Scholar · View at Scopus
  2. D. Kirpichnikov and J. R. Sowers, “Diabetes mellitus and diabetes-associated vascular disease,” Trends in Endocrinology and Metabolism, vol. 12, no. 5, pp. 225–230, 2001. View at Google Scholar · View at Scopus
  3. K. Pyorala, M. Laakso, and M. Uusitupa, “Diabetes and atherosclerosis: an epidemiologic view,” Diabetes/Metabolism Reviews, vol. 3, no. 2, pp. 463–524, 1987. View at Google Scholar · View at Scopus
  4. S. M. Haffner, S. Lehto, T. Rönnemaa, K. Pyörälä, and M. Laakso, “Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction,” The New England Journal of Medicine, vol. 339, no. 4, pp. 229–234, 1998. View at Publisher · View at Google Scholar · View at Scopus
  5. É. Toussirot, G. Streit, N. U. Nguyen et al., “Adipose tissue, serum adipokines, and ghrelin in patients with ankylosing spondylitis,” Metabolism, vol. 56, no. 10, pp. 1383–1389, 2007. View at Publisher · View at Google Scholar · View at Scopus
  6. J. Vendrell, M. Broch, N. Vilarrasa et al., “Resistin, adiponectin, ghrelin, leptin, and proinflammatory cytokines: relationships in obesity,” Obesity Research, vol. 12, no. 6, pp. 962–971, 2004. View at Google Scholar · View at Scopus
  7. D. M. Nathan, “Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the american diabetes association and the european association for the study of diabetes,” Diabetes Care, vol. 32, no. 3, pp. e37–e38, 2009. View at Publisher · View at Google Scholar · View at Scopus
  8. V. Fonseca, J. Rosenstock, R. Patwardhan, and A. Salzman, “Effect of metformin and rosiglitazone combination therapy in patients with type 2 diabetes mellitus: a randomized controlled trial,” Journal of the American Medical Association, vol. 283, no. 13, pp. 1695–1702, 2000. View at Google Scholar · View at Scopus
  9. D. M. Nathan, “Initial management of glycemia in type 2 diabetes mellitus,” The New England Journal of Medicine, vol. 347, no. 17, pp. 1342–1349, 2002. View at Publisher · View at Google Scholar · View at Scopus
  10. S. E. Inzucchi, “Oral antihyperglycemic therapy for type 2 diabetes: scientific review,” Journal of the American Medical Association, vol. 287, no. 3, pp. 360–372, 2002. View at Google Scholar · View at Scopus
  11. D. C. Klonoff, J. B. Buse, L. L. Nielsen et al., “Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years,” Current Medical Research and Opinion, vol. 24, no. 1, pp. 275–286, 2008. View at Publisher · View at Google Scholar · View at Scopus
  12. A.-D. Cui, N.-N. Gai, X.-H. Zhang et al., “Decreased serum obestatin consequent upon TRIB3 Q84R polymorphism exacerbates carotid atherosclerosis in subjects with metabolic syndrome,” Diabetology and Metabolic Syndrome, vol. 4, no. 1, pp. 1–5, 2012. View at Google Scholar
  13. G. Alloatti, E. Arnoletti, E. Bassino et al., “Obestatin affords cardioprotection to the ischemic-reperfused isolated rat heart and inhibits apoptosis in cultures of similarly stressed cardiomyocytes,” American Journal of Physiology, vol. 299, no. 2, pp. H470–H481, 2010. View at Publisher · View at Google Scholar · View at Scopus
  14. J. V. Zhang, P.-G. Ren, O. Avsian-Kretchmer et al., “Medicine: obestatin, a peptide encoded by the ghrelin gene, opposes ghrelin's effects on food intake,” Science, vol. 310, no. 5750, pp. 996–999, 2005. View at Publisher · View at Google Scholar · View at Scopus
  15. S. S. Qader, R. Håkanson, J. F. Rehfeld, I. Lundquist, and A. Salehi, “Proghrelin-derived peptides influence the secretion of insulin, glucagon, pancreatic polypeptide and somatostatin: a study on isolated islets from mouse and rat pancreas,” Regulatory Peptides, vol. 146, no. 1–3, pp. 230–237, 2008. View at Publisher · View at Google Scholar · View at Scopus
  16. M. Kapica, M. Zabielska, I. Puzio et al., “Obestatin stimulates the secretion of pancreatic juice enzymes through a vagal pathway in anaesthetized rats—preliminary results,” Journal of Physiology and Pharmacology, vol. 58, no. 3, pp. 123–130, 2007. View at Google Scholar · View at Scopus
  17. J. V. Zhang, P.-G. Ren, O. Avsian-Kretchmer et al., “Medicine: Obestatin, a peptide encoded by the ghrelin gene, opposes ghrelin's effects on food intake,” Science, vol. 310, no. 5750, pp. 996–999, 2005. View at Publisher · View at Google Scholar · View at Scopus
  18. V. Catalán, J. Gómez-Ambrosi, F. Rotellar et al., “The obestatin receptor (GPR39) is expressed in human adipose tissue and is down-regulated in obesity-associated type 2 diabetes mellitus,” Clinical Endocrinology, vol. 66, no. 4, pp. 598–601, 2007. View at Publisher · View at Google Scholar · View at Scopus
  19. S. Mohr-Kahaly, “New diagnostic criteria for diabetes and coronary artery disease: insights from an angiographic study,” Journal of the American College of Cardiology, vol. 37, no. 6, pp. 1543–1550, 2001. View at Publisher · View at Google Scholar · View at Scopus
  20. T. Nakahara, T. Harada, D. Yasuhara et al., “Plasma obestatin concentrations are negatively correlated with body mass index, insulin resistance index, and plasma leptin concentrations in obesity and anorexia nervosa,” Biological Psychiatry, vol. 64, no. 3, pp. 252–255, 2008. View at Publisher · View at Google Scholar · View at Scopus
  21. U. Gurriarán-Rodríguez, O. Al-Massadi, A. Roca-Rivada et al., “Obestatin as a regulator of adipocyte metabolism and adipogenesis,” Journal of Cellular and Molecular Medicine, vol. 15, no. 9, pp. 1927–1940, 2011. View at Google Scholar
  22. R. Granata, D. Gallo, R. M. Luque et al., “Obestatin regulates adipocyte function and protects against diet-induced insulin resistance and inflammation,” The FASEB Journal, vol. 26, no. 8, pp. 3393–3411, 2012. View at Publisher · View at Google Scholar
  23. X. Qi, L. Li, G. Yang et al., “Circulating obestatin levels in normal subjects and in patients with impaired glucose regulation and type 2 diabetes mellitus,” Clinical Endocrinology, vol. 66, no. 4, pp. 593–597, 2007. View at Publisher · View at Google Scholar · View at Scopus
  24. V. Catalán, J. Gómez-Ambrosi, F. Rotellar et al., “The obestatin receptor (GPR39) is expressed in human adipose tissue and is down-regulated in obesity-associated type 2 diabetes mellitus,” Clinical Endocrinology, vol. 66, no. 4, pp. 598–601, 2007. View at Publisher · View at Google Scholar · View at Scopus
  25. D. H. St-Pierre, F. Settanni, I. Olivetti et al., “Circulating obestatin levels in normal and Type 2 diabetic subjects,” Journal of Endocrinological Investigation, vol. 33, no. 4, pp. 211–214, 2010. View at Google Scholar · View at Scopus
  26. H. N. Hodis, W. J. Mack, L. LaBree et al., “The role of carotid arterial intima—media thickness in predicting clinical coronary events,” Annals of Internal Medicine, vol. 128, no. 4, pp. 262–269, 1998. View at Google Scholar · View at Scopus
  27. M. W. Lorenz, H. S. Markus, M. L. Bots, M. Rosvall, and M. Sitzer, “Prediction of clinical cardiovascular events with carotid intima-media thickness: a systematic review and meta-analysis,” Circulation, vol. 115, no. 4, pp. 459–467, 2007. View at Publisher · View at Google Scholar · View at Scopus
  28. T. Temelkova-Kurktschiev, C. Koehler, E. Henkel, and M. Hanefeld, “Leukocyte count and fibrinogen are associated with carotid and femoral intima-media thickness in a risk population for diabetes,” Cardiovascular Research, vol. 56, no. 2, pp. 277–283, 2002. View at Publisher · View at Google Scholar · View at Scopus
  29. G. Brohall, A. Odén, and B. Fagerberg, “Carotid artery intima-media thickness in patients with Type 2 diabetes mellitus and impaired glucose tolerance: a systematic review,” Diabetic Medicine, vol. 23, no. 6, pp. 609–616, 2006. View at Publisher · View at Google Scholar · View at Scopus
  30. S. H. Kim, S. J. Lee, E. S. Kang et al., “Effects of lifestyle modification on metabolic parameters and carotid intima-media thickness in patients with type 2 diabetes mellitus,” Metabolism, vol. 55, no. 8, pp. 1053–1059, 2006. View at Publisher · View at Google Scholar · View at Scopus
  31. E. J. Lee, H. J. Kim, J. M. Bae et al., “Relevance of common carotid intima-media thickness and carotid plaque as risk factors for ischemic stroke in patients with type 2 diabetes mellitus,” American Journal of Neuroradiology, vol. 28, no. 5, pp. 916–919, 2007. View at Google Scholar · View at Scopus
  32. E. Kellokoski, A. Kunnari, M. Jokela, S. Mäkelä, Y. A. Kesäniemi, and S. Hörkkö, “Ghrelin and obestatin modulate early atherogenic processes on cells: enhancement of monocyte adhesion and oxidized low-density lipoprotein binding,” Metabolism, vol. 58, no. 11, pp. 1572–1580, 2009. View at Publisher · View at Google Scholar · View at Scopus
  33. G. Alloatti, E. Arnoletti, E. Bassino et al., “Obestatin affords cardioprotection to the ischemic-reperfused isolated rat heart and inhibits apoptosis in cultures of similarly stressed cardiomyocytes,” American Journal of Physiology, vol. 299, no. 2, pp. H470–H481, 2010. View at Publisher · View at Google Scholar · View at Scopus
  34. A. J. Agnew, E. Robinson, C. M. McVicar et al., “The gastrointestinal peptide obestatin induces vascular relaxation via specific activation of endothelium-dependent NO signalling,” British Journal of Pharmacology, vol. 166, no. 1, pp. 327–338, 2012. View at Publisher · View at Google Scholar · View at Scopus
  35. E. Kellokoski, A. Kunnari, M. Jokela, S. Mäkelä, Y. A. Kesäniemi, and S. Hörkkö, “Ghrelin and obestatin modulate early atherogenic processes on cells: enhancement of monocyte adhesion and oxidized low-density lipoprotein binding,” Metabolism, vol. 58, no. 11, pp. 1572–1580, 2009. View at Publisher · View at Google Scholar · View at Scopus